Foundational to Artugen’s technology is the discovery that certain strains of Bacillus velezensis are capable of delivering therapeutics benefits without colonizing the gastrointestinal tract.
Artugen applies sound pharmacologic principles to ensure that our therapeutic-bacteria-based products engage with proven disease mechanisms, thereby providing effective treatment of infection and inflammation.
Artugen’s bacterial strains (ARTs) are selected and dosed as human therapeutics using the rigorous principles established for conventional small molecules. ART strains behave as therapeutics factories, producing multiple disease-targeting compounds with a variety of activities such as bacteria-killing, toxin degradation, gliadin degradation, and many others.
Artugens’s lead candidate, ART24 is being studied in a clinical trial for the prevention of Clostridioides difficile infection (CDI) recurrence. In preclinical studies, ART24 has been shown to both kill C. difficile and destroy its toxins.
The company is also exploring the therapeutic value of ARTs in other diseases that involve gastrointestinal inflammation.